Mavixan (Rizatriptan Benzoate)

Mavixan belongs to the triptan class and is used to treat migraine‑related conditions.

• Migraine with aura: provides rapid relief of headache pain and associated symptoms.
• Migraine without aura: reduces headache severity and duration.
• Acute migraine attacks: aborts the attack when taken at the first sign of headache.

• Rizatriptan selectively binds to serotonin 5‑HT1B and 5‑HT1D receptors on cranial blood vessels and trigeminal nerve terminals. Activation causes vasoconstriction of intracranial arteries and inhibits release of pro‑inflammatory neuropeptides, thereby alleviating migraine headache and associated photophobia, phonophobia, and nausea.

Rizatriptan may cause a range of adverse reactions, most of which are mild to moderate.

Common Side Effects

• Chest discomfort or tightness
• Tingling or numbness in fingers or toes
• Nausea or stomach upset
• Dizziness or light‑headedness
• Fatigue or drowsiness
• Dry mouth

Serious or Rare Side Effects

• Coronary vasospasm or myocardial ischemia
• Serotonin syndrome, especially with other serotonergic agents
• Severe allergic reactions (anaphylaxis, angioedema)
• Hypertension or sudden increase in blood pressure
• Stroke or transient ischemic attack
• Severe abdominal pain or vomiting

Before prescribing Mavixan, clinicians should evaluate patient history and potential risk factors.

• Cardiovascular disease: avoid in patients with coronary artery disease or uncontrolled hypertension.
• Hemiplegic or basilar migraine: contraindicated due to risk of cerebrovascular events.
• Concomitant serotonergic drugs: assess risk of serotonin syndrome.
• Pregnancy and lactation: use only if potential benefit justifies potential risk; data are limited.
• Storage: Store below 25°C: keep in the original packaging, protect from moisture and direct sunlight.

Rizatriptan can interact with several medication classes, requiring careful management.

Major Interactions (Avoid)

• Monoamine oxidase inhibitors (MAOIs): risk of severe hypertension and serotonin syndrome.
• Other triptans or ergot derivatives: additive vasoconstrictive effects.
• Selective serotonin reuptake inhibitors (SSRIs) / serotonin‑norepinephrine reuptake inhibitors (SNRIs): increased serotonin toxicity.

Moderate Interactions (Monitor Closely)

• Strong CYP3A4 inhibitors (e.g., ketoconazole, erythromycin): may raise rizatriptan plasma levels.
• Antihypertensive agents: possible additive blood pressure lowering.
• Oral contraceptives: may slightly increase migraine frequency; monitor efficacy.